PDE4NPD

Parasite-specific cyclic nucleotide phosphodiesterase inhibitors to target Neglected Parasitic Diseases

 Coordinatore STICHTING VU-VUMC 

 Organization address address: DE BOELELAAN 1105
city: AMSTERDAM
postcode: 1081 HV

contact info
Titolo: Prof.
Nome: Rob
Cognome: Leurs
Email: send email
Telefono: +31 205987579

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 7˙799˙246 €
 EC contributo 6˙000˙000 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-03-01   -   2018-02-28

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    STICHTING VU-VUMC

 Organization address address: DE BOELELAAN 1105
city: AMSTERDAM
postcode: 1081 HV

contact info
Titolo: Prof.
Nome: Rob
Cognome: Leurs
Email: send email
Telefono: +31 205987579

NL (AMSTERDAM) coordinator 1˙215˙666.00
2    UNIVERSITY OF KENT

 Organization address address: THE REGISTRY CANTERBURY
city: CANTERBURY, KENT
postcode: CT2 7NZ

contact info
Titolo: Dr.
Nome: Andrew
Cognome: Massoura
Email: send email
Telefono: +44 1227 823256

UK (CANTERBURY, KENT) participant 787˙968.00
3    UNIVERSITY OF GLASGOW

 Organization address address: University Avenue
city: GLASGOW
postcode: G12 8QQ

contact info
Titolo: Mr.
Nome: Joe
Cognome: Galloway
Email: send email
Telefono: +44 141 330 3884

UK (GLASGOW) participant 786˙759.00
4    UNIVERSITEIT ANTWERPEN

 Organization address address: PRINSSTRAAT 13
city: ANTWERPEN
postcode: 2000

contact info
Titolo: Mrs.
Nome: Anne
Cognome: Adams
Email: send email
Telefono: +32 3 265 30 28
Fax: +32 3 265 30 11

BE (ANTWERPEN) participant 778˙548.00
5    FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V

 Organization address address: Hansastrasse 27C
city: MUENCHEN
postcode: 80686

contact info
Titolo: Mr.
Nome: Michael
Cognome: Prestele
Email: send email
Telefono: +49 89 1205 2738

DE (MUENCHEN) participant 656˙227.28
6    IOTA Pharmaceuticals Ltd

 Organization address address: COWLEY ROAD ST JOHNS INNOVATION CENTRE
city: CAMBRIDGE
postcode: CB4 0WS

contact info
Titolo: Dr.
Nome: Paul
Cognome: England
Email: send email
Telefono: +44 1727373761

UK (CAMBRIDGE) participant 545˙156.00
7    AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

 Organization address address: CALLE SERRANO 117
city: MADRID
postcode: 28006

contact info
Titolo: Ms.
Nome: Ana Maria
Cognome: De La Fuente
Email: send email
Telefono: +34 915681709

ES (MADRID) participant 398˙664.00
8    STICHTING TOP INSTITUTE PHARMA

 Organization address address: GALILEIWEG 8
city: LEIDEN
postcode: 2333 BD

contact info
Titolo: Dr.
Nome: Herman
Cognome: Verheij
Email: send email
Telefono: 31611280582

NL (LEIDEN) participant 300˙000.00
9    Theodor Bilharz Research Institute

 Organization address address: El Nil street
city: Giza
postcode: 12411

contact info
Titolo: Dr.
Nome: Amr
Cognome: Radwan
Email: send email
Telefono: 201226000000

EG (Giza) participant 299˙938.00
10    FUNDACAO OSWALDO CRUZ

 Organization address address: AVENIDA BRASIL 4365
city: RIO DE JANEIRO
postcode: 21040 900

contact info
Titolo: Mrs.
Nome: Maria
Cognome: De Nazaré Correia Soeiro
Email: send email
Telefono: +5521 25621368
Fax: +5521 25909741

BR (RIO DE JANEIRO) participant 199˙419.00
11    EUROPEAN SCREENINGPORT GMBH

 Organization address address: SCHNACKENBURGALLEE 114
city: HAMBURG
postcode: 22525

contact info
Titolo: Dr.
Nome: Sheraz
Cognome: Gul
Email: send email
Telefono: +49 40303764276
Fax: +49 40303764100

DE (HAMBURG) participant 31˙654.72

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

discovery    class    diseases    human    platform    pdes    optimization    efficient    smes    phenotypic    pde    validation    drug    npd    inhibitors    parasitic    centric    public    hit    parasite    screening   

 Obiettivo del progetto (Objective)

'This project aims to unite global efforts to target the highly druggable class of enzymes called cyclic nucleotide phosphodiesterases (PDEs) in the fight for neglected parasitic diseases (NPD). It will establish a drug discovery platform, PDE4NPD, that combines phenotypic screening with efficient target-centric drug discovery, including target validation, various strategies for compound screening, PDE hit and lead optimization, safety and toxicology assessments and evaluation of anti-parasitic activity. The platform will make use of the target class expertise that the participating SMEs have gained when developing drugs for human and parasite PDEs, while all public partners offer proven experience in the field of NPD. The SMEs will adopt and progress existing PDE inhibitors that are in different stages of the drug discovery pipeline (i.e., target validation, hit and lead optimization). The current portfolio of inhibitors have clinical potential for treating sleeping sickness, Chagas' disease and leishmaniasis. Finding novel hits and leads for the PDEs that are associated with helminth diseases is also foreseen. The platform is open for targeting other NPD, and a broad panel of phenotypic screens (including malaria) is available to test PDE inhibitors. The phenotypic screening is performed by world-renowned groups, including two institutes in endemic countries. By capturing human and parasite PDE-related data in annotated chemogenomics databases, PDE-4-NPD will achieve the knowledge accumulation that is typical for target-centric approaches, thereby making the NPD drug development more efficient and enabling the SMEs to take advantage of the molecular understanding that is key for developing new medicines. The PDE4NPD platform constitutes an ideal basis for creating fruitful collaborations with both public and private partners word-wide.'

Altri progetti dello stesso programma (FP7-HEALTH)

MEFOPA (2010)

European Project on Mendelian Forms of Parkinson’s Disease

Read More  

NEUROMICS (2012)

Integrated European –omics research project for diagnosis and therapy in rare neuromuscular and neurodegenerative diseases

Read More  

EPIDIACAN (2010)

Development of sensitive methodologies for exploitation of early epigenetic marker diagnosis in major types of cancer

Read More